Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony nowotwór złośliwy z mutacją IDH1 (np. białaczka, rak jelit, glejak mózgu)
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Prawidłowa funkcja wątroby i nerek potwierdzona badaniami krwi
- •Kobiety w wieku rozrodczym muszą mieć negatywny test ciąży
- •Brak przyjmowania olutasidenib przez ostatnie 2 tygodnie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
UCI Irvine Health
Orange, United States
New York Presbyterian Hospital-Columbia University Medical Center
New York, United States
Trial contact
Kay Patel
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.